Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.5% Higher – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price rose 5.5% on Monday . The stock traded as high as $6.50 and last traded at $6.36. Approximately 5,209,043 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 6,721,588 shares. The stock had previously closed at $6.03.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Jefferies Financial Group cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Price Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average is $6.77 and its two-hundred day moving average is $7.16. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the firm posted ($0.43) EPS. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% compared to the same quarter last year. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the completion of the transaction, the director now owns 7,098,428 shares of the company’s stock, valued at $44,152,222.16. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,788 shares of company stock valued at $724,691. 15.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals in the third quarter worth approximately $25,000. Farther Finance Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. KBC Group NV grew its stake in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at $69,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.